Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNEUROPHARMACOLOGY

Galantamine Is an Allosterically Potentiating Ligand of Neuronal Nicotinic but Not of Muscarinic Acetylcholine Receptors

Marek Samochocki, Anja Höffle, Andreas Fehrenbacher, Ruth Jostock, Jürgen Ludwig, Claudia Christner, Martin Radina, Marion Zerlin, Christoph Ullmer, Edna F. R. Pereira, Hermann Lübbert, Edson X. Albuquerque and Alfred Maelicke
Journal of Pharmacology and Experimental Therapeutics June 2003, 305 (3) 1024-1036; DOI: https://doi.org/10.1124/jpet.102.045773
Marek Samochocki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anja Höffle
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas Fehrenbacher
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruth Jostock
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jürgen Ludwig
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudia Christner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Radina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marion Zerlin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christoph Ullmer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edna F. R. Pereira
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hermann Lübbert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edson X. Albuquerque
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alfred Maelicke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Galantamine (Reminyl), an approved treatment for Alzheimer's disease (AD), is a potent allosteric potentiating ligand (APL) of human α3β4, α4β2, and α6β4 nicotinic receptors (nAChRs), and of the chicken/mouse chimeric α7/5-hydroxytryptamine3 receptor, as was shown by whole-cell patch-clamp studies of human embryonic kidney-293 cells stably expressing a single nAChR subtype. Galantamine potentiates agonist responses of the four nAChR subtypes studied in the same window of concentrations (i.e., 0.1–1 μM), which correlates with the cerebrospinal fluid concentration of the drug at the recommended daily dosage of 16 to 24 mg. At concentrations >10 μM, galantamine acts as an nAChR inhibitor. The other presently approved AD drugs, donepezil and rivastigmine, are devoid of the nicotinic APL action; at micromolar concentrations they also block nAChR activity. Using five CHO-SRE-Luci cell lines, each of them expressing a different human muscarinic receptor, and a reporter gene assay, we show that galantamine does not alter the activity of M1–M5 receptors, thereby confirming that galantamine modulates selectively the activity of nAChRs. These studies support our previous proposal that the therapeutic action of galantamine is mainly produced by its sensitizing action on nAChRs rather than by general cholinergic enhancement due to cholinesterase inhibition. Galantamine's APL action directly addresses the nicotinic deficit in AD.

Footnotes

  • This work was supported by grants from the Deutsche Forschungsgemeinschaft, the Stiftung Rheinland-Pfalz für Innovation, and the Fonds der Chemischen Industrie (all to A.M.). Further funds and materials were obtained from Janssen Research Foundation (to A.M. and E.X.A.) and from Biofrontera Pharmaceuticals AG (Leverkusen) (to A.M.). E.X.A. has received additional grants from the United States Army Medical Research and Development Command (DAMD-17-95-c-5063), and the United States Public Health Service (NS25296).

  • Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

  • DOI: 10.1124/jpet.102.045773.

  • ABBREVIATIONS: AD, Alzheimer's disease; ACh, acetylcholine; ChE, cholinesterase; mAChR, muscarinic acetylcholine receptor; nAChR, nicotinic acetylcholine receptor; APL, allosterically potentiating ligand; 5-HT, 5-hydroxytryptamine; HEK, human embryonic kidney; DMEM, Dulbecco's modified Eagle's medium; PCR, polymerase chain reaction; RT-PCR, reverse transcription-PCR; CHO, Chinese hamster ovary; SRE, serum-response element.

    • Received November 7, 2002.
    • Accepted February 6, 2003.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 305 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 305, Issue 3
1 Jun 2003
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Galantamine Is an Allosterically Potentiating Ligand of Neuronal Nicotinic but Not of Muscarinic Acetylcholine Receptors
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleNEUROPHARMACOLOGY

Galantamine Is an Allosterically Potentiating Ligand of Neuronal Nicotinic but Not of Muscarinic Acetylcholine Receptors

Marek Samochocki, Anja Höffle, Andreas Fehrenbacher, Ruth Jostock, Jürgen Ludwig, Claudia Christner, Martin Radina, Marion Zerlin, Christoph Ullmer, Edna F. R. Pereira, Hermann Lübbert, Edson X. Albuquerque and Alfred Maelicke
Journal of Pharmacology and Experimental Therapeutics June 1, 2003, 305 (3) 1024-1036; DOI: https://doi.org/10.1124/jpet.102.045773

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleNEUROPHARMACOLOGY

Galantamine Is an Allosterically Potentiating Ligand of Neuronal Nicotinic but Not of Muscarinic Acetylcholine Receptors

Marek Samochocki, Anja Höffle, Andreas Fehrenbacher, Ruth Jostock, Jürgen Ludwig, Claudia Christner, Martin Radina, Marion Zerlin, Christoph Ullmer, Edna F. R. Pereira, Hermann Lübbert, Edson X. Albuquerque and Alfred Maelicke
Journal of Pharmacology and Experimental Therapeutics June 1, 2003, 305 (3) 1024-1036; DOI: https://doi.org/10.1124/jpet.102.045773
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • KRM-II-81 Analogs
  • Substituted Tryptamine Activity at 5-HT Receptors and SERT
  • VTA muscarinic M5 receptors and effort-choice behavior
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics